Title : Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.

Pub. Date : 2021 Jan 11

PMID : 33432012






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Tacrolimus (TAC) pharmacokinetics is influenced by the donor CYP3A5 genotype and the age of pediatric liver recipients. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
2 Tacrolimus (TAC) pharmacokinetics is influenced by the donor CYP3A5 genotype and the age of pediatric liver recipients. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
3 TAC concentration/weight-adjusted dose ratio was significantly lower in recipients from CYP3A5*1/*3 donors or with extra-large (GRWR > 5%) or large (GRWR 3-5%) grafts. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
4 In conclusion, TAC starting dose could be guided according to the donor CYP3A5 genotype and GRWR, allowing for a quicker achievement of target concentrations and eventually reducing the risk of rejection. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens